News
| 27 June 2017 |
Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across EuropeLONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today regulatory appr… |
| 22 June 2017 |
Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory AffairsLONDON, June 22, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announces the appointment… |
| 6 June 2017 |
Holding(s) in CompanyTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) |
| 6 June 2017 |
Holding(s) in Company
|
| 5 June 2017 |
Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study for RPL554 Following Acceptance of IND Application by FDALONDON, June 05, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with signifi… |
| 30 May 2017 |
Holding(s) in Company
|
| 30 May 2017 |
Holding(s) in Company
|
| 25 May 2017 |
Holding(s) in Company
|
| 23 May 2017 |
Verona Pharma to Present at Jefferies 2017 Global Healthcare ConferenceLONDON, May 23, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with signifi… |
| 23 May 2017 |
Holding(s) in Company |
Realising multiple value creation opportunities with a unique respiratory product RPL554
AGM presentation
27 June 2016
The Lancet Respiratory Medicine
Peer-reviewed paper in the Lancet's highly-respected medication journal
Targeting unmet needs
210m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients
Verona Pharma plc
3 More London Riverside,
London SE1 2RE
T: +44 (0)203 283 4200
E: info@veronapharma.com
© Verona Pharma plc 2017
